Nuvation Bio Reports Durable IBTROZI Efficacy in ROS1+ NSCLC
New York, New York, U.S., September 15, 2026 Nuvation Bio Inc. has announced new analyses from the pivotal TRUST-I...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
New York, New York, U.S., September 15, 2026 Nuvation Bio Inc. has announced new analyses from the pivotal TRUST-I...
Milford, Massachusetts, U.S., September 14, 2026 Waters Corporation has announced the global commercial launch of the BD FACSDiscoverâ„¢ A7...
